Get the Stockscreener App
339.93
1.07%
-3.67
After Hours:
346.56
6.63
+1.95%
Praxis Precision Medicines Inc stock is traded at $339.93, with a volume of 514.41K.
It is down -1.07% in the last 24 hours and up +15.64% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
See More
Previous Close:
$343.60
Open:
$348.04
24h Volume:
514.41K
Relative Volume:
1.11
Market Cap:
$9.47B
Revenue:
$7.46M
Net Income/Loss:
$-303.27M
P/E Ratio:
-25.24
EPS:
-13.4668
Net Cash Flow:
$-249.12M
1W Performance:
+6.16%
1M Performance:
+15.64%
6M Performance:
+492.73%
1Y Performance:
+1,046%
1-Day Range:
$330.00
$350.00
1-Week Range:
$312.73
$352.78
52-Week Range:
$28.79
$356.00
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
339.93 | 9.57B | 7.46M | -303.27M | -249.12M | -13.47 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Strong Buy |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-02-26 | Initiated | Wells Fargo | Equal Weight |
| Dec-15-25 | Reiterated | Oppenheimer | Outperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Praxis Precision gains as lead asset accepted for FDA review - MSN
Deutsche Bank Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $437 - Moomoo
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $437 From $412, Maintains Buy Rating - marketscreener.com
PRAX Reiterated by Needham -- Price Target Maintained at $510 - GuruFocus
FDA accepts Praxis Precision Medicines’ NDA for ulixacaltamide in essential tremor - Investing.com Australia
Praxis Precision NDA for Ulixacaltamide in Essential Tremor - TipRanks
FDA accepts Praxis (PRAX) ulixacaltamide NDA for adult essential tremor - Stock Titan
Jones Trading reiterates Praxis Precision Medicines stock Buy rating on FDA filing acceptance - Investing.com UK
Jones Trading reiterates Praxis Precision Medicines stock Buy rating on FDA filing acceptance By Investing.com - Investing.com India
Why Is Praxis Precision Stock Soaring Tuesday? - Benzinga
Jefferies reiterates Praxis Precision Medicines stock rating on FDA review - Investing.com UK
Praxis Precision Medicines stock rating reiterated at Buy by BTIG - Investing.com
Jefferies reiterates Praxis Precision Medicines stock rating on FDA review By Investing.com - Investing.com Australia
Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $510 - Moomoo
Praxis Precision Medicines Shares Rise After FDA Accepts New Drug Application - marketscreener.com
Praxis Precision gets FDA review for lead asset (PRAX:NASDAQ) - Seeking Alpha
Praxis Precision Medicines Announces FDA Acceptance of NDA for Ulixacaltamide HCl for Essential Tremor Treatment, Target Action Date Set for January 29, 2027 - Quiver Quantitative
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor - Bitget
FDA starts Praxis review for essential tremor drug, decision due Jan. 2027 - Stock Titan
(PRAX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026 - National Today
7 million Americans with essential tremor see a first positive Phase 3 program - Stock Titan
Raymond James Initiates Praxis Precision Medicines at Strong Buy With $815 Price Target - marketscreener.com
Raymond James initiates Praxis Precision Medicines stock coverage with Strong Buy - Investing.com
A Look At Praxis Precision Medicines (PRAX) Valuation After Positive Elsunersen Seizure Reduction Data - simplywall.st
Praxis Precision Medicines (PRAX) reports $926M 2025 cash balance, extended runway - MSN
PRAX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Wolfe Research Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $500 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $500 to $1,245 - Moomoo
Praxis Adds To Neuroscience Momentum With Epilepsy Trial Success - Citeline News & Insights
H.C. Wainwright reiterates Praxis Precision stock rating on trial data By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Praxis Precision stock rating on trial data - Investing.com
HC Wainwright Reiterates Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX) - MarketBeat
HC Wainwright & Co. Reiterates Buy Rating for PRAX with $1245 Ta - GuruFocus
Praxis Precision Medicines Announces Positive EMBRAVE Part A Trial Results for Elsunersen in Pediatric SCN2A Epileptic Encephalopathy - Minichart
Praxis Precision Medicines reports positive trial results for elsunersen and FDA review of relutrigine - Investing.com Australia
Praxis reports positive elsunersen trial in pediatric epilepsies - TipRanks
Praxis Precision Medicines reports positive trial results for elsunersen and FDA review of relutrigine By Investing.com - Investing.com South Africa
Praxis Precision reports positive Phase 1/2 elsunersen results; FDA sets PDUFA for relutrigine - TradingView — Track All Markets
Praxis (PRAX) reports positive elsunersen seizure data and FDA priority review for relutrigine - Stock Titan
Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential (PRAX) - Seeking Alpha
PRAX: BTIG Reiterates Buy Rating and Maintains Price Target | PR - GuruFocus
Praxis rises on elsunersen data for SCN2A encephalopathy in children - MSN
PRAX: BTIG Reiterates Buy Rating and Maintains Price Target | PRAX Stock News - gurufocus.com
BTIG Research Reaffirms "Buy" Rating for Praxis Precision Medicines (NASDAQ:PRAX) - marketbeat.com
Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In TrialPraxis Precision Medicine (NAS - Benzinga
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy - Investing News Network
Praxis Precision Medicines Announces Positive Results From The Embrave Part A Trial Of Elsunersen In Patients With Scn2a Early-Onset Developmental And Epileptic Encephalopathy - TradingView — Track All Markets
In a nine-patient Praxis trial, children had 77% fewer seizures - Stock Titan
A Look At Praxis Precision Medicines (PRAX) Valuation After FDA Priority Review For Relutrigine - Yahoo Finance
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):